Home › Trial NCT02278458
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
- Trial IDNCT02278458
- StatusUnknown
- PhasePhase 1
- Study typeInterventional
- SponsorBetta Pharmaceuticals Co., Ltd.
- Enrollment24
- Start date2014-10
- ConditionsPancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.